REGENXBIO to Participate in Upcoming Investor Conferences
March 07, 2018 16:05 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., March 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...
REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
March 06, 2018 16:01 ET
|
REGENXBIO Inc.
Completed dosing of third cohort in RGX-314 Phase I clinical trial for wet AMDContinuing dosing of second cohort in RGX-501 Phase I/II clinical trial for HoFHAnticipate presenting topline data from...
REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
February 27, 2018 16:05 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
February 08, 2018 16:05 ET
|
REGENXBIO Inc.
Clinical trial evaluates one-time treatment for wet AMD using NAV® AAV8 gene therapy18 patients have been dosed at leading retinal surgery centers in the United StatesAnticipate reporting topline data...
REGENXBIO to Participate in Upcoming Investor Conferences
February 07, 2018 16:05 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies
January 23, 2018 16:10 ET
|
REGENXBIO Inc.
- REGENXBIO has established internal capability to produce NAV AAV across multiple platforms and at scale of up to 200L - Agreement with FUJIFILM secures access to dedicated cGMP suite capacity...
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
January 08, 2018 08:00 ET
|
REGENXBIO Inc.
AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMAAmended agreement permits assignment by AveXis upon a change of control without REGENXBIO’s...
REGENXBIO Provides Year-End 2017 Corporate Update
January 04, 2018 16:05 ET
|
REGENXBIO Inc.
- Initiated third cohort dosing of RGX-314 Phase I clinical trial for wet AMD - - Initiated second cohort dosing of RGX-501 Phase I/II clinical trial for HoFH - - Anticipate completing dosing and...
REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II
December 19, 2017 07:00 ET
|
REGENXBIO Inc.
Novel, one-time, direct-to-CNS treatment for MPS II focused toward potentially preventing the progression of cognitive deficitsClinical trial expected to enroll children with MPS IIAnticipate...
REGENXBIO to Present at Upcoming Investor Conferences
November 22, 2017 07:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Nov. 22, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...